Skip to Content
Merck
  • Cardiac oxidative stress in a mouse model of neutral lipid storage disease.

Cardiac oxidative stress in a mouse model of neutral lipid storage disease.

Biochimica et biophysica acta (2013-07-23)
Astrid Schrammel, Marion Mussbacher, Sarah Winkler, Guenter Haemmerle, Heike Stessel, Gerald Wölkart, Rudolf Zechner, Bernd Mayer
ABSTRACT

Cardiac oxidative stress has been implicated in the pathogenesis of hypertrophy, cardiomyopathy and heart failure. Systemic deletion of the gene encoding adipose triglyceride lipase (ATGL), the enzyme that catalyzes the rate-limiting step of triglyceride lipolysis, results in a phenotype characterized by severe steatotic cardiac dysfunction. The objective of the present study was to investigate a potential role of oxidative stress in cardiac ATGL deficiency. Hearts of mice with global ATGL knockout were compared to those of mice with cardiomyocyte-restricted overexpression of ATGL and to those of wildtype littermates. Our results demonstrate that oxidative stress, measured as lucigenin chemiluminescence, was increased ~6-fold in ATGL-deficient hearts. In parallel, cytosolic NADPH oxidase subunits p67phox and p47phox were upregulated 4-5-fold at the protein level. Moreover, a prominent upregulation of different inflammatory markers (tumor necrosis factor α, monocyte chemotactant protein-1, interleukin 6, and galectin-3) was observed in those hearts. Both the oxidative and inflammatory responses were abolished upon cardiomyocyte-restricted overexpression of ATGL. Investigating the effect of oxidative and inflammatory stress on nitric oxide/cGMP signal transduction we observed a ~2.5-fold upregulation of soluble guanylate cyclase activity and a ~2-fold increase in cardiac tetrahydrobiopterin levels. Systemic treatment of ATGL-deficient mice with the superoxide dismutase mimetic Mn(III)tetrakis (4-benzoic acid) porphyrin did not ameliorate but rather aggravated cardiac oxidative stress. Our data suggest that oxidative and inflammatory stress seems involved in lipotoxic heart disease. Upregulation of soluble guanylate cyclase and cardiac tetrahydrobiopterin might be regarded as counterregulatory mechanisms in cardiac ATGL deficiency.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Esterase Isoenzyme 1 porcine liver, recombinant, recombinant, expressed in E. coli, ≥30.0 U/g
Sigma-Aldrich
Esterase from Bacillus subtilis, recombinant, expressed in E. coli, ≥10 U/mg
Sigma-Aldrich
Esterase from rabbit liver, lyophilized powder, ≥30 units/mg protein
Sigma-Aldrich
Esterase from porcine liver, ammonium sulfate suspension, ≥150 units/mg protein (biuret)
Sigma-Aldrich
Esterase from porcine liver, lyophilized powder, ≥15 units/mg solid
Sigma-Aldrich
Esterase from porcine liver, lyophilized, powder, slightly beige, ≥50 U/mg
Sigma-Aldrich
Carboxylesterase 2 human, recombinant, expressed in mouse NSO cells, ≥95% (SDS-PAGE)
Sigma-Aldrich
Esterase from Bacillus stearothermophilus, ≥0.2 U/mg
Sigma-Aldrich
Esterase Pseudomonas fluorescens, recombinant from E. coli, ≥4 U/mg
Sigma-Aldrich
Carboxylesterase 1 isoform b human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Carboxylesterase 1 isoform c human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Carboxylesterase 2 human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Esterase from Bacillus stearothermophilus, recombinant, expressed in E. coli, ≥4.0 U/mg